PBMCs and Other Specimens from RCC Patients Receiving Treatment with Immunomodulatory Agents , Canada
Objective: We are interested in immunological changes, including altered anticancer T cell responses, in patients with kidney cancer following treatment with immunomodulatory agents. These include programmed death-1 (PD-1)-based checkpoint inhibitors and mammalian target of rapamycin (mTOR) inhibitors.
|Registered Biobank Name||PBMCs and Other Specimens from RCC Patients Receiving Treatment with Immunomodulatory Agents|
|Biobank Leader||S.M. Mansour Haeryfar|
|Email for biobank inquiries||Mansour.Haeryfar@schulich.uwo.ca|
|Principal Investigator||Dr. S.M. Mansour Haeryfar|